anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Transfusional therapy is used to cure anemia but raises the risk of hepatic iron overload (IO), which triggers oxidative stress damage, inflammation, and failure even fibrosis. microRNAs play a vital role in developing hepatic diseases. This study presented the mechanism by which IO induce hepatic inflammation through microRNAs. In this study, microRNA expression profiling in the liver was observed after IO for 2 weeks, in which the target microRNA will be found. IO activating the miR-146α/TRAF6/NF-κB pathway was validated, and the molecular mechanism of the IO-induced decrease of miR-146α in the liver was studied in vivo and in vitro. The expression of TRAF6/NF-κB (p65)-dependent inflammatory factors increased, whereas the expression of miR-146α decreased during the IO-induced inflammatory response in the liver. The reduced expression of HNF4α caused by HIF1α and miR-34α may decrease the expression of miR-146α. Overexpression of miR-146α alleviated the hepatic inflammatory response caused by IO. Our findings indicate that miR-146α is a key factor in inducing hepatic IO inflammation, which will be another potential target to prevent IO-induced hepatic damage.
The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to purify polysaccharide compositions, including polysaccharide compositions isolated from Ganoderma lucidum (Reishi). The methods and reagents of the disclosure may also be used to identify innate immunity receptors and cell types that bind to polysaccharide compositions (including polysaccharide compositions associated with pathogens), whereupon modulators of the identified receptors can then be obtained. The fusion proteins also may be used to inhibit the interaction between a polysaccharide composition and an innate immunity receptor on a cell surface. The methods and reagents of the disclosure are used in one embodiment to determine that the CLEC5A/MDL1/DLVR1 innate immunity receptor on macrophages interacts with Dengue virus (DV), and that CLEC5A/MDL1/DLVR1 is responsible for DV-mediated secretion of proinflammatory cytokines from macrophages. The disclosure also provides CLEC5A/MDL1/DLVR1 antibodies that prevent the secretion of proinflammatory cytokines by DV-infected macrophages.
Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is TRPV4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma  in situ , a pre-neoplastic lesion and normal tissues. TRPV4 was also found to be elevated mostly in invasive breast cancer cell lines and less so in non-invasive breast cancer cell lines. These data led us to hypothesize that TRPV4 confer early traits of metastatic cancer cells. Functional studies revealed that silencing of TRPV4 expression diminished breast cancer cell migration and invasion significantly but not proliferation. Silencing expression of TRPV4 in metastatic breast cancer cells also reduced the number and size of metastatic colonies in mice. This supports the notion that TRPV4 is an attractive drug target to curb metastasis. Further experimentations suggested that the functional effect of TRPV4 on breast cancer cellular processes was associated with regulation of intracellular Ca2+, cell plasticity and expression of cell-cell adhesion proteins such as beta-catenin and E-cadherin. The latter two events have obvious implications in cancer invasion and intravasation/extravasation. We have also made novel observations that activation of TRPV4 by PDD led to activation of AKT and FAK pathways, both shown to be important to cell migration. In particular, downregulation of E-cadherin and b-catenin following TRPV4 activation has been shown to be mediated by the AKT pathway. Collectively, our data suggest that activation of Ca2+ dependent cascades and pathways associated with cell migration mediate TRPV4 function in breast cancer metastasis.
PROBLEM TO BE SOLVED: To obtain a temporary hair dye, safety for human body excellent in dispersibility of pigment, sticking tendency, having properties such as slow sedimentation velocity, etc., by dispersing black titanium oxide without using a specific dispersing agent and without using carbon black or graphite. SOLUTION: The black titanium oxide is dispersed in a solvent of C<=4 alcohol using copolymer of N-methacryloylethyl-N,N'-dimethylammonium.α-N- methylcarboxybetaine and butylmethacrylate as the dispersing agent. The black titanium oxide is formulated in amount of 0.3-10%, preferably 2-8% in a primary hair dying agent, though black titanium oxide alone can dye white hair, but natural colored hair is obtained by combined use of red iron oxide, yellow iron oxide, black iron oxide allowing to tone to brown color form tinged with red or yellowish black. The mixing ratio of at least one kind of pigments selected from red iron oxide, black iron oxide and yellow iron oxide with black titanium oxide is preferably more than 10wt.%. of black titanium oxide based of the pigments. Ethanol is preferred as alcohol solvent of 4C <= alcohol.
PROBLEM TO BE SOLVED: To perform processing of a medical image which is an interpretation object to be referred in contents of a remark with a simple operation, allowing the image to be correctly and easily understood, when preparing a medical image interpretation report.SOLUTION: A link correspondence range is identified for a character string in a remark column of a report (S15). A content is specified so as to perform drag and drop operation into a display part of the link correspondence range (S16). When specifying a character string, content address information is attached (S17 to S19), and the character string in the link correspondence range is identified and displayed (S20). Then, it is determined whether information related to the linked content is displayed (S21). When the display is instructed, a new content is prepared on the basis of the content with the address information linked and a content which is different from that content, and a protocol for displaying is embedded in a hyper link (S22). After preparing the report, the file is saved so as to finish all the series of processing, and the file is transmitted for example to a report preparation requester.
Participants will receive one capsule of the marketed reference formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
The invention relates to a medicinal preparation of dapoxetine hydrochloride, belonging to the technical field of medicine. Specifically, the medicinal preparation is a directly-compressed tablet. The directly-compressed tablet of dapoxetine hydrochloride employs dapoxetine hydrochloride with a particle size D90 of 40 to 150 [mu]m as an active component and lactose and microcrystalline cellulose as fillers, wherein the microcrystalline cellulose is a composition of two types of microcrystalline cellulose, i.e., PH302 and KG802. The invention also provides a preparation method for the directly-compressed tablet of dapoxetine hydrochloride. The preparation method is feasible in production and has the advantages of simple operation and conservation of man-hour and cost compared with conventional processes for tablets. The directly-compressed tablet of dapoxetine hydrochloride prepared by using the method has the advantages of fast dissolving-out performance and qualified and stable quality compared with tablets in the prior art.
Patients receive pembrolizumab IV on day 1 of week 1, and undergo high dose EBRT for 2 fractions on 2 consecutive days during week 4. Patients also undergo salvage surgery during week 8. Beginning week 11, patients receive pembrolizumab IV every 3 weeks for up to 18 doses in the absence of disease progression or unacceptable toxicity. Patients also undergo IORT for 1 fraction during week 11. Treatment with pembrolizumab may continue beyond initial progression per investigator-assessed clinical benefit and if the patient is tolerating pembrolizumab.
Diabetic retinopathy (DR) is the leading cause of blindness and visual loss in people with diabetes. It has been suggested that the progression of DR is associated with chronic inflammation and oxidative stress. The aim of the present work was to evaluate the ability of the natural compound madecassic acid (MEA) to reverse the negative impact of streptozotocin (STZ) on retinal injury in rats. Diabetic rats induced by STZ were treated with MEA at the doses of 10 and 20 mg/kg bw for 8 weeks. The study compared the efficacy of the drug in controlling high blood sugar levels and its impact on therapeutic targets such as SOD, CAT, GPx, NF-κB, TNF-α, IL-6, IL-1β, VEGF, IGF, bFGF and Keap1/Nrf-2 pathway. The results showed that the treatment with MEA significantly restored the retinal SOD, CAT, and GPx levels in diabetic rats to the near-normal levels. Moreover, the level of inflammatory mediators (TNF-α, IL-1β, IL-6) and growth factors (VEGF, IGF, bFGF) was significantly lower in retinas of animals treated with MEA as compared to retinas of diabetic animals. The study also established that MEA administration reduced the NF-κB protein and altered the Nrf-2/Keap1 pathway thereby reducing oxidative stress and inflammation. Furthermore, the use of MEA prevented the progression of the retinal capillary basement membrane thickening. It has been found that MEA offers significant protection to the retina and therefore, the compound may be useful in the treatment of DR in humans.
The dedicated (DED) set comprised a ventilator for MPV (Trilogy 100, Philips Respironics; with dedicated software, with a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger, with a smart flexible tube support system and with a silicone made mouthpiece designed as a straw.
The invention relates to preparation of a celecoxib-vitamin E prodrug nano-drug delivery system based on electrostatic spraying. Celecoxib (CEL) is linked to Vitamin E (VE) using dithiodiacetic acid to produce celecoxib-vitamin E prodrug (CEL-SVE). On this basis, celecoxib-vitamin E prodrug nanoparticles (CEL-SVE NPs) were further prepared. The prodrug nanoparticles have several characteristics: the average grain diameter is smaller than 400 and nm, and is uniformly distributed in a sphere-like shape,the drug loading rate can reach 6 mg.mL calculated by celecoxib  ‑1  . Gradually hydrolyzing under acidic condition and being stable under pH 7.4. The prodrug nanoparticles can increase the solubility of celecoxib, remarkably improve the bioavailability of celecoxib, increase the targeting effect of celecoxib on tumor cells, and remarkably improve the anticancer, anti-inflammatory and analgesic effects of celecoxib. The stability is good, the security is high, has great market prospect.
The main objective of the trial is to investigate if doxapram is safe and effective in reducing the composite outcome of death and neurodevelopmental impairment/severe disability at 2 years corrected age as compared to placebo. This multicenter double blinded randomized placebo-controlled superiority trial will be conducted in multiple neonatal intensive care units in the Netherlands and Belgium, including 8 years follow-up. After written informed-consent the patients will be randomized into the doxapram treatment group or the placebo treatment group. Randomization will be stratified based on center and gestational age \< or \>= 26 weeks.

The participating departments include Dutch and Belgian Neonatal Intensive care units. The units include both academic and non-academic level III and IV units that are specialized in the care for critically ill and preterm born infants. Postnatal ages of patients at doxapram start vary from directly after birth up to months for the most-preterm born infants.

Blinded continuous doxapram or placebo (glucose 5%) will be infused as long as needed. Therapy is down titrated or stopped based on the patients' condition. If endotracheal intubation is needed study drug is stopped. After extubation study drug may be restarted. Switch to gastro-enteral administration is allowed if no iv-access is needed for other reasons. Next to study drug infusion, there will be no other study-related interventions. All outcome variables are already collected as standard of care. In a subset of patients doxapram plasma levels will be determined to validate the doxapram pharmacokinetic (PK) model. Blood will only be collected during routine blood sampling, with a maximum amount of 0.6 ml. Economic and cost-effectiveness evaluation will be performed. The national protocol for preterm birth advices follow-up at 2, 5.5 and 8 years respectively, as in the current study. Additional questionnaires will be used to collect data on the quality of life of patients and their parents.
If patients are in the control arm, they will continue to receive Standard Best Practice (SBP) and their data will be held by the researcher until after the second interview (4 weeks). After this time, they will be contacted by the H2H nurse to receive the intervention and will be interviewed and followed up as for the fast track group.
The utility model provides an improved magnetic medicated plaster, which is composed of a protective facing layer, a magnetic sheet layer provided with magnetic sheet base materials, a medicine layer and a back substrate material layer coated with an adhesive. The utility model is characterized in that the magnetic sheet layer forms a quincunx provided with four petals. A cross space region is formed in the middle of the magnetic sheet layer. Traditional Chinese medicinal powder with curative treatment functions is arranged in the cross space region. Medicine can be intensively acted to skins under a formed ambient surrounding magnetic field, and an obvious therapeutic effect can be achieved. The magnetic medicated plaster is particularly suitable for disease symptoms of arthritis, muscular soreness, traumatic injury, etc.
This research study was designed to determine the effects of functional electrical stimulation (FES) rowing and a drug called zoledronic acid in bone health in individuals who have suffered a spinal cord injury (SCI). The investigators hoped to learn if zoledronic acid treatment would increase bone mineral density in persons with chronic spinal cord injury. This was designed and conducted as a three center study with multiple investigators. The investigators also had a goal to find out if zoledronic acid is safe for persons with SCI without causing too many side effects.

The Prime recipient of funding is Spaulding Rehabilitation Hospital (SRH). Dr. Leslie Morse is the Principal Investigator for the study, the coordination of the study was located at Spaulding Rehabilitation Hospital. Through a sub-award a research group from the Veterans Administration of Boston Healthcare System was contracted to conduct DXA scans, blood draws and zoledronic acid administration to support this study. Through another sub-award from SRH, another Investigator from Massachusetts General Hospital (MGH) participated conducting CT scans for the study. All adverse events related to this study were to be monitored and recorded by investigators at SRH.

Seventy subjects age 18 years or older and wheelchair dependent at least 50% of the time because of an SCI were enrolled. Enrollment and initial screening for the study and follow up was performed at SRH. After enrollment the subjects were randomized to 1) FES-rowing alone or 2) FES-rowing plus a 1-time infusion of zoledronic acid. Following a variable period of strength training which was necessary for preparing quads and hamstrings for extended FES use, enrolled participants were planned to begin a regular rowing program for 12 months at the Cardiovascular Laboratory at the Spaulding Rehabilitation Hospital . DXA scans to measure bone mineral density were planned to be performed at the VA Boston Healthcare System-Jamaica Plain Campus (VABHS) three times during the study on all participants. In addition, 25 subjects in each arm of the study were planned to receive CT scans of their knees at MGH at the beginning and end of the study. Up to 20 subjects were to have an additional CT scan (at MGH) six months into rowing. Research blood samples were planned to be collected at VABHS five times during duration of the study and stored at the VA for further study of molecular markers of bone turnover. All participants were expected to be screened for renal function and calcium and vitamin D levels at the beginning and end of the study, with additional renal screening done before and after the zoledronic acid infusion. Calcium and vitamin D supplements were to be provided to each subject throughout the study. Those with insufficient vitamin D levels were to be provided additional repletion and planned to be periodically rechecked. Up to 15 male subjects were asked to have two echocardiograms at one of the SRH sites - one at the beginning of the study and the other halfway through the year-long rowing regimen.
BACKGROUND: This study aimed to explore discrepancies in adolescents with chronic illness and their parents' perceptions of family resilience, as well as the relationship between these differences and the psychological adjustment of adolescents with chronic illness.
METHODS: A cross-sectional study was conducted. A total of 264 dyads of parents (77.7% mothers, mean age 41.60 years, SD = 6.17) and adolescents (48.5% girls, mean age 12.68 years, SD = 2.11) with chronic illness were recruited through convenience sampling from three children's hospitals in Wenzhou, Hangzhou, and Shanghai, China between June 2022 and May 2023. The Chinese version of the Family Resilience Scale and the Psychological Adjustment Scale, which are commonly used measures with good reliability and validity, were employed to assess family resilience and psychological adaption, respectively. The data were analyzed using polynomial regression and response surface analysis.
RESULTS: Adolescents with chronic illness reported higher family resilience than their parents (t=-2.80, p < 0.05). The correlations between family resilience and adolescents' psychological adjustment reported by the adolescents (r = 0.45-0.48) were higher than parents (r = 0.18-0.23). In the line of congruence, there were positive linear (a1 = 1.09-1.60, p < 0.001) and curvilinear (a2=-1.38∼-0.72, p < 0.05) associations between convergent family resilience and adolescents' psychological adjustment. In the line of incongruence, when adolescents reported lower family resilience than parents, adolescents had a lower level of psychological adjustment (a3=-1.02∼-0.45, p < 0.05). Adolescents' sociability decreased when the perceived family resilience of parent-adolescent dyads converged (a4 = 1.36, p < 0.01).
CONCLUSION: The findings highlighted the importance of considering the discrepancies and congruence of family resilience in the parent-child dyads when developing interventions to improve the psychological adjustment of adolescents with chronic illness. Interventions aimed at strengthening family communication to foster the convergence of perceptions of family resilience in parent-adolescent dyads were warranted.
The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a text warning "WARNING: High in added sugar" (task 2).
PURPOSE:To produce an inexpensively obtainable drug effective for treating bovine adiponecrosis, having low side effects and high safety, by coating the surface of lipid particles containing an unsaturated fatty acid with a protein hardened coating film. CONSTITUTION:Protein dissolved in warm water is blended with a granular lipid (e.g. colza oil) containing an unsaturated fatty acid having predissolved an emulsifying agent, emulsified and homogenized. Then the emulsion is mixed with a hard film forming agent (e.g. glutaraldehyde) and dried by spray drying, etc., to give the objective substance. The blending ratio is 5-90wt.% lipid, 0.01-3wt.% emulsifying agent, 10-95wt.% protein and 0.01-5wt.% hard film- forming agent. The drug is in a powdery state, directly administered orally to bovine as it is or mixed with a feed, etc., and administered. The taken treating agent avoids hydrogenation in a bovine rumen, is digested in an abomasum and absorbed in intestinum tenue.
PROBLEM TO BE SOLVED: To obtain a polymerizable filler-containing material for dentistry, low in viscosity, giving a cured product improved in mechanical characteristics, and lowered in polymerization contraction by using a specific silica organo sol as a component for the dental material. SOLUTION: This material uses as a filler a sol which is an amorphous SiO2 particle sol in a liquid organic dispersant and is not agglomerated. The surfaces of the SiO2 particles are modified with an organic material, and the SiO2 particles have an average particle size of 10-100nm. The sol is use in an amount of 1-50wt.% based on the dental material. The SiO2 particles are contained in an amount of 10-70wt.%, preferably 20-55wt.%, based on the sol. A liquid organic dispersant (e.g. hexanediol diacrylate, a 2-hydroxyethyl methacrylate, a urethane methacrylate) may be used in the dental material. A polymerizable organic binder (e.g. triethylene glycol dimethacrylate) is more preferably contained. A polymerization initiator and a polymerization accelerator may further be contained.
Introduction: Hyperfunctional ectopic parathyroid glands in the mediastinum pose a challenge to diagnosis and require optimal surgical management. Video-assisted thoracoscopic surgery (VATS) has emerged as a promising minimally invasive approach, offering potential benefits in terms of both patient comfort and oncological principles. This study aimed to evaluate the effectiveness and safety of VATS for the treatment of hyperfunctional ectopic parathyroid glands in the mediastinum. Methods: Among the 538 patients with mediastinal tumors who underwent thoracoscopic surgery at Istanbul University (2008-2021), 11 exhibited hyperfunctional ectopic parathyroid glands. The localization of the glands was performed using various diagnostic techniques, including neck ultrasound, sestamibi scan, CT (computerized tomography), and SPECT (Single-photon emission computed tomography). VATS (Video-assisted thoracoscopic surgery) was used to remove ectopic parathyroid glands in all 11 patients, with no need for conversion to open surgery. Results: The pathological results showed that VATS successfully removed the ectopic glands in all 11 patients. Serum parathyroid hormone (PTH) levels were monitored intraoperatively, and frozen sections were used to confirm the presence of parathyroid adenomas in all cases. Postoperative analysis showed that PTH levels dropped by at least 50% within 10-15 minutes after adenoma removal. Conclusion: VATS is a safe and effective method for the treatment of hyperfunctional ectopic parathyroid glands in the mediastinum with a low risk of complications.
PURPOSE: An anticancer agent containing Hades as a Akt negative regulator is provided to suppress proliferation and presence of cancer cells. CONSTITUTION: An Akt(protein kinase B) negative regulator contains Hades protein with an amino acid of sequence number 2 or a gene encoding the same as an active ingredient. The gene encoding Hades contains a base of sequence number 1. The gene is inserted into a recombinant expression vector. Hades contains RING finger-domain and has E3-ubiquitin ligase activity. An anticancer agent contains Hades protein or the gene encoding the same as an active ingredient. The anticancer agent functions as an Akt(protein kinase B) negative regulator.